EUVIMEDOpdag EUVIMED
Crossref

Spatial Robustness of Prostate Cancer Biomarkers Evaluated by Spatial Transcriptomics

Kristofer G Taylor iD, Bjarne Johannessen, Ian G Mills, Morten B Rye, Karol Axcrona, Rolf I Skotheim iD

The Prostate · 2026-06 · 86 (8) · 929-940

DOI: 10.1002/pros.70164 ↗

At a glance

Journal article in The Prostate, published online on 2026-03-30. Written by Kristofer G Taylor and 5 co-authors. Institution: Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway. Major MEDLINE topics: Prostatic Neoplasms, Biomarkers, Tumor. 39 references. Funded by: Norwegian Cancer Society, Kreftforeningen.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Background

Prognostic biomarker panels identified through bulk sequencing approaches have shown utility in localized prostate cancer but are limited by underlying molecular heterogeneity. Spatial transcriptomics offers a complementary approach to investigate spatial gene expression patterns and the tissue‐ and cell‐type‐associated localization of their constituent biomarker genes.

Methods

Using publicly available data, we analyzed biomarker genes from four prognostic panels (Oncotype DX, Prolaris, Decipher, and ProClass—an in‐house candidate panel) across 37 tissue sections from two patients with localized high‐grade disease. Analyses were performed to quantify biomarker gene abundance across tissue sections using the Visium Spatial Platform, assess spatial variability using global Moran's I, and identify biomarker localization to specific biological niches through spatial co‐expression network analysis.

Results

Tissue type composition varied markedly between tissue sections. Several genes from Oncotype DX ( KLK2 , AZGP1 , TPM2 , GSN, FLNC, COL1A1 ) and Decipher ( ANO7 , MYBPC1 ) were consistently spatially variable across the samples (mean global Moran's I > 0.1). In contrast, cell cycle‐associated genes, predominantly in the Prolaris panel, exhibited weak expression limited to a small proportion of sample spots. ProClass genes also showed limited expression, impeding robust spatial analysis. Weighted gene co‑expression network analysis identified spatial modules closely aligned to histopathological annotations, linking most Oncotype DX genes to stromal networks, whereas Decipher genes spanned diverse networks.

Conclusions

Spatial transcriptomics revealed significant variability in biomarker gene expression across highly heterogeneous prostate cancer tissue sections from two patients, providing proof‐of‐concept for its potential use in prognostic biomarker panel research. Several Oncotype DX genes were notably spatially variable, predominantly localizing to stromal regions, whilst the majority of biomarker genes from other panels exhibited non‐spatial patterns. Although low‐abundance genes may be impacted by current technological limitations, integrating spatial data into biomarker research holds promise for developing “spatially robust” panels to provide reliable prognostic information amidst molecular heterogeneity in prostate cancer.

Subjects

MeSH terms (MEDLINE)

Prostatic NeoplasmsBiomarkers, TumorMaleHumansSpatial TranscriptomicsGene Expression ProfilingTranscriptomeGene Expression Regulation, NeoplasticPrognosis

Author keywords

expression signaturesheterogeneityprognostic biomarkersprostate cancerspatial transcriptomics

Substances

Biomarkers, Tumor

Authors and institutions

  • Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital-Radiumhospitalet, Oslo, Norway.
  • Department of Clinical and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway.
  • Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK.
  • Department of Biomedicine, Aarhus University, Aarhus, Denmark.
  • Department of Urology, Akershus University Hospital, Lørenskog, Norway.
  • Department of Informatics, University of Oslo, Oslo, Norway.

ORCID profiles: Kristofer G Taylor, Rolf I Skotheim

Funding

  • Norwegian Cancer Society
  • Kreftforeningen

Cite

APA

Taylor, K. G., Johannessen, B., Mills, I. G., Rye, M. B., Axcrona, K., & Skotheim, R. I. (2026). Spatial Robustness of Prostate Cancer Biomarkers Evaluated by Spatial Transcriptomics. The Prostate, 86(8), 929-940. https://doi.org/10.1002/pros.70164

Vancouver

Taylor KG, Johannessen B, Mills IG, Rye MB, Axcrona K, Skotheim RI. Spatial Robustness of Prostate Cancer Biomarkers Evaluated by Spatial Transcriptomics. The Prostate. 2026;86(8):929-940. doi:10.1002/pros.70164

BibTeX
@article{Taylor2026,
  author = {Taylor, Kristofer G and Johannessen, Bjarne and Mills, Ian G and Rye, Morten B and Axcrona, Karol and Skotheim, Rolf I},
  title = {Spatial Robustness of Prostate Cancer Biomarkers Evaluated by Spatial Transcriptomics},
  journal = {The Prostate},
  year = {2026},
  volume = {86},
  number = {8},
  pages = {929--940},
  doi = {10.1002/pros.70164}
}
Start for free →